CID-103 vs HLX15

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: CD38 · full Multiple Myeloma pipeline

CID-103

Developed by CASI Pharmaceuticals, Inc.

Phase 1 in Multiple Myelomamonoclonal antibody (fully human IgG1, anti-CD38)
Weak signal

NCT04758767 · Phase 1 · completed

All participants received CID-103 with no placebo or comparator arm and no blinding, so the design cannot show whether the antibody works better than another option. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

Adverse events (approximately 18 months after study start): In 10 patients with previously treated relapsed and/or refractory multiple myeloma, CID-103 given as 30 mg/150 mg, 150 mg/300 mg, 150 mg/600 mg and 150 mg/900 mg doses was generally safe and well tolerated overall, but there was no beneficial impact on any patient's multiple myeloma. Nine of the 10 patients discontinued study drug due to progressive disease or lack of clinical benefit, and no further clinical trials with CID-103 are planned. (not_applicable)

Result source: NCT04758767

HLX15

Developed by Dr. Reddy's Laboratories under a licence from Shanghai Henlius Biotech

Phase 3 in Multiple Myelomamonoclonal antibody (anti-CD38 biosimilar candidate)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: May 2027 · NCT07477587 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCID-103HLX15
PFS, median—Not reported—Trial running · NCT06895512
OS, median—Not reported—Trial running · NCT06895512
ORR—Not reported—Trial running · NCT06895512
VGPR or better—Not reported—Trial running · NCT06895512
MRD negativity—Not reported—Trial running · NCT06895512

PFS, median

CID-103
—Not reported
HLX15
—Trial running · NCT06895512

OS, median

CID-103
—Not reported
HLX15
—Trial running · NCT06895512

ORR

CID-103
—Not reported
HLX15
—Trial running · NCT06895512

VGPR or better

CID-103
—Not reported
HLX15
—Trial running · NCT06895512

MRD negativity

CID-103
—Not reported
HLX15
—Trial running · NCT06895512
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

CID-103: no structured comparison results are available for Multiple Myeloma.

HLX15: no structured comparison results are available for Multiple Myeloma.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CID-103's landscape · HLX15's landscape